Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic; Department of Pathology, Hôpital La Pitié Salpêtrière, Faculty of Medicine UPMC Paris VI, France; Department of Pathology, CHU Pontchaillou, Université de Rennes 1, Rennes, France.
Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic; Department of Pathology, Hôpital La Pitié Salpêtrière, Faculty of Medicine UPMC Paris VI, France; Department of Pathology, CHU Pontchaillou, Université de Rennes 1, Rennes, France.
Ann Diagn Pathol. 2016 Apr;21:59-64. doi: 10.1016/j.anndiagpath.2015.11.003. Epub 2016 Jan 22.
Renal angiomyoadenomatous tumor has been described in 2000, followed by description of clear cell papillary renal cell carcinoma in 2006. Discussions about possible relationship of both tumors were published since their description. The main differential diagnostic feature was considered presence/absence of fibroleiomyomatous stroma-relationship of renal angiomyoadenomatous tumor in stroma-rich tumors. However, it was shown that stroma is reactive and nonneoplastic by its nature and that all other histologic, immunohistochemical, and molecular-genetic features of both entities are identical. In upcoming World Health Organization classification of renal tumors (2016), both lesions are considered as a single entity (clear cell papillary renal cell carcinoma [CCPRCC]). Most published cases followed the benign/indolent clinical course. In addition, most tumors has normal status of VHL gene (methylation, LOH 3p, mutations); however, CCPRCC was referred in patients with VHL syndrome. Another issue covered by this review is possible relationship of CCPRCC and "renal cell carcinoma with leiomyomatous stroma" (RCCLS). Renal cell carcinoma with leiomyomatous stroma shows clear cell cytology and abundant leiomyomatous stroma. Some of RCCLS are positive for cytokeratin 7; some are negative. Similar situation exists for relation of RCCLS and VHL gene abnormalities. It is so far unclear whether any relation between CCPRCC and RCCLS exists. From all published studies, it seems that these tumors are less likely related to each other.
肾血管肌腺瘤于 2000 年被描述,随后于 2006 年描述了透明细胞乳头状肾细胞癌。自这两种肿瘤被描述以来,就已经对它们之间可能存在的关系进行了讨论。主要的鉴别诊断特征被认为是纤维平滑肌基质的存在/不存在——肾血管肌腺瘤与富含基质的肿瘤的关系。然而,已经表明基质具有反应性和非肿瘤性,其本质是非肿瘤性的,并且这两种实体的所有其他组织学、免疫组织化学和分子遗传学特征都是相同的。在即将发布的 2016 年世界卫生组织(WHO)肾脏肿瘤分类中,这两种病变被认为是单一实体(透明细胞乳头状肾细胞癌[CCPRCC])。大多数已发表的病例遵循良性/惰性的临床过程。此外,大多数肿瘤的 VHL 基因(甲基化、LOH3p、突变)状态正常;然而,CCPRCC 也见于 VHL 综合征患者。本综述还涉及另一个问题,即 CCPRCC 与“具有平滑肌基质的肾细胞癌”(RCCLS)之间可能存在的关系。具有平滑肌基质的肾细胞癌具有透明细胞细胞学和丰富的平滑肌基质。一些 RCCLS 对细胞角蛋白 7 呈阳性;有些则呈阴性。RCCLS 与 VHL 基因异常之间的关系也存在类似情况。到目前为止,尚不清楚 CCPRCC 和 RCCLS 之间是否存在任何关系。从所有已发表的研究来看,这些肿瘤似乎不太可能相互关联。